This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.

life sciences
Industries

Rare Disease

Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.

Follow us on LinkedIn: CRA on Rare Disease 

We are rare disease specialists.

CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.

  • 50+
    Rare disease areas covered
  • 500+
    Rare disease engagements since 2019

Our rare disease offerings span across the product lifecycle.

  • Early development
    Discover
    • Pipeline opportunity assessment
    • Diagnostics & screening
    • Early Pricing Marketing Access (PMA)
    • Licensing / commercially reasonable efforts disputes
  • Late development
    Develop
    • Market access & evidence generation strategy
    • Payer value proposition
    • Patient finding
    • Landscape assessment & policy shaping
  • Launch
    Deliver
    • Launch pricing strategy
    • Payer negotiation
    • Launch excellence
    • Stakeholder engagement
    • Competitive simulations
    • Uptake and diffusion
  • Life cycle & LOE
    Defend
    • Indication & geographic expansion
    • Competitor response strategies
    • Price/access/uptake benchmarking and assessments
    • LOE strategies

Engagements

  • 01
    Strategic and statistical consulting involving rare disease pharmaceuticals
    The CRA expert reviewed data from a variety of existing studies and analyzed limitations and opportunities regarding the use of such data. Client relied upon...
    View engagement
  • 02
    Developed dynamic GTN model to guide pricing and contracting strategy for a rare disease asset
    A leading pharmaceutical company engaged CRA’s Life Sciences consultants for support in developing a pricing and contracting strategy for a rare disease asset
    View engagement
  • 03
    Evaluating the potential impact of cross-border healthcare for gene therapies
    CRA's Rare Disease team evaluated the dynamics of cross-border healthcare using secondary research to explore current precedence and/or previous product...
    View engagement
See more Rare Disease engagements

Contact a Rare Disease expert.

See all Rare Disease experts

Latest insights

See all Rare Disease insights

Recent and Upcoming Events

See all Rare Disease events

Related capabilities

Subscribe to receive our latest Insights.

Subscribe